Reporting from ESMO Virtual Congress 2020, Stephen Johnston features the results from the monarchE study on abemaciclib and from the PALLAS trial with palbociclib, as adjuvant treatment in patients with HR positive HER2 negative early Breast Cancer.
He elaborates possible reasons why outcome in these trials was very different, and insists on the importance of risk factors assessment, as well as management of adverse events to improve treatment compliance.
Abstracts:
- LBA12 - PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus adjuvant endocrine therapy alone for HR+/HER2- early breast cancer
- LBA5_PR - Abemaciclib for the adjuvant treatment of high-risk early breast cancer
Simultaneous publication: https://ascopubs.org/doi/full/10.1200/JCO.20.02514
This video was supported with educational grants from Bayer, Daiichi Sankyo and Novartis